Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sushma Saksena is active.

Publication


Featured researches published by Sushma Saksena.


Hepatology | 2007

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Paul Angulo; Jason M. Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C. Farrell; Felicity Enders; Sushma Saksena; Alastair D. Burt; John P. Bida; Keith D. Lindor; Schuyler O. Sanderson; Marco Lenzi; Leon A. Adams; James G. Kench; Terry M. Therneau; Christopher P. Day

Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highest risk for progressing to end‐stage liver disease. We constructed and validated a scoring system consisting of routinely measured and readily available clinical and laboratory data to separate NAFLD patients with and without advanced fibrosis. A total of 733 patients with NAFLD confirmed by liver biopsy were divided into 2 groups to construct (n = 480) and validate (n = 253) a scoring system. Routine demographic, clinical, and laboratory variables were analyzed by multivariate modeling to predict presence or absence of advanced fibrosis. Age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio were independent indicators of advanced liver fibrosis. A scoring system with these 6 variables had an area under the receiver operating characteristic curve of 0.88 and 0.82 in the estimation and validation groups, respectively. By applying the low cutoff score (−1.455), advanced fibrosis could be excluded with high accuracy (negative predictive value of 93% and 88% in the estimation and validation groups, respectively). By applying the high cutoff score (0.676), the presence of advanced fibrosis could be diagnosed with high accuracy (positive predictive value of 90% and 82% in the estimation and validation groups, respectively). By applying this model, a liver biopsy would have been avoided in 549 (75%) of the 733 patients, with correct prediction in 496 (90%). Conclusion: a simple scoring system accurately separates patients with NAFLD with and without advanced fibrosis, rendering liver biopsy for identification of advanced fibrosis unnecessary in a substantial proportion of patients. (HEPATOLOGY 2007;45:846–854.)


Gut | 2005

Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis

Emanuele Albano; Elisa Mottaran; Matteo Vidali; E Reale; Sushma Saksena; Giuseppa Occhino; Alastair D. Burt; Christopher P. Day

Aims: Factors responsible for the progression of non-alcoholic fatty liver disease (NAFLD) to more severe liver injury are poorly understood. In the present study, we investigated the association between immune reactions triggered by oxidative stress and stage of NAFLD. Methods: Titres of IgG against human serum albumin adducted with malondialdehyde (MDA-HSA) or arachidonic acid hydroperoxide (AAHP) and against oxidised cardiolipin (Ox-CL) were measured in 167 NAFLD patients with steatosis only (n = 79), steatohepatitis (n = 74), or steatosis plus cirrhosis (n = 14), and in 59 age and sex matched controls. Results: Circulating IgG against lipid peroxidation products was significantly higher (p<0.001) in NAFLD patients than in controls. Oxidative stress dependent immune responses were not associated with obesity, type 2 diabetes, or with serum cholesterol, ferritin, or aminotransferase levels. Titres of lipid peroxidation related antibodies were also independent of the extent of steatosis and were similarly distributed in patients with and without necroinflammation. In contrast, the same antibodies were significantly increased in patients with advanced fibrosis or cirrhosis. Logistic regression analysis confirmed that anti-MDA antibodies were independently associated with progression of NALFD and that NAFLD patients with titres of anti-MDA-HSA antibodies above the control threshold value had a threefold (relative risk 2.82 (95% confidence interval 1.35–5.90); p = 0.007) higher risk of having advanced fibrosis/cirrhosis than patients whose antibody titres were within the control range. Conclusions: These results indicate that the presence of immune reactions triggered by oxidative stress can be an independent predictor of progression of NAFLD to advanced fibrosis.


Journal of Gastroenterology and Hepatology | 2002

Non-alcoholic steatohepatitis: Definitions and pathogenesis

Christopher P. Day; Sushma Saksena

This description remains appropriate because nonalcoholic fatty liver disease (NAFLD) can range from simple steatosis, through NASH and fibrosis to cirrhosis with fat. 2 In addition to fat, the histological diagnosis of NASH ideally requires evidence of (i) hepatocyte injury, manifest by swollen or ‘ballooned’ cells; (ii) an inflammatory infiltrate, predominantly neutrophils, with or without (iii) fibrosis, typically perivenular/pericellular in distribution. Each of these features can be graded to derive a score recently proposed by Brunt et al. 3 Rigorous exclusion of alcohol as a cause of the histology is, of course required and this is best achieved by a combination of repeated questioning of patients and ideally friends/relatives, frequent random blood alcohol estimations and measurement of mean cell corpuscular volume (MCV). No pattern of liver blood test abnormalities is either specific or sensitive enough to distinguish between NAFLD and alcohol-related liver disease.


Hepatology | 2003

159 Natural history and determinants of disease progression in non alcoholic fatty liver disease-good and bad news

Sushma Saksena


Journal of Hepatology | 2003

Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease

Sushma Saksena; Julian Leathart; Ann K. Daly; Christopher P. Day


Hepatology | 2003

720 Oxidative stress is an independent risk factor for the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis

Emanuele Albano; Elisa Mottaran; Matteo Vidali; Emanuela Reale; Sushma Saksena; Giuseppa Occhino; Alastair D. Burt; Christopher P. Day


58th Annual Meeting of the American Association for the Study of Liver Diseases | 2007

Genetic evidence that lipid trafficking plays a key role in fibrosis in non alcoholic fatty liver disease

De, Alwis, Nm; Ann K. Daly; Gp Aithal; E Henderson; Julian Leathart; Sushma Saksena; T Shaw; Christopher P. Day


Hepatology: 54th Annual Meeting of the American Association for the Study of Liver Disease | 2003

Oxidative stress is an independent risk factor for the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis

Emanuele Albano; Elisa Mottaran; Matteo Vidali; E Reale; Sushma Saksena; Giuseppa Occhino; Alastair D. Burt; Christopher P. Day


Gut | 2003

Genetic evidence supporting the two-hit model of NASH pathogenesis

Sushma Saksena; Julian Leathart; Alastair D. Burt; Ofw James; Ann K. Daly; Christopher P. Day


Journal of Hepatology | 1998

Are alcoholic liver disease and fatty liver consequences of an abnormal hepatic steroid metabolism

Sushma Saksena; Pj Wood; Paul M. Stewart; Elwyn Elias

Collaboration


Dive into the Sushma Saksena's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuseppa Occhino

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Geoffrey C. Farrell

Australian National University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James G. Kench

Royal Prince Alfred Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge